Surrogate Endpoints for Late Kidney Transplantation Failure

Area of Science:

• Nephrology and Transplant Medicine
• Clinical Trial Design
• Regulatory Science

Background:

• Late graft failure in kidney transplantation is complex and multifactorial.
• Current primary endpoints in transplantation studies focus on short-term efficacy and safety, which may not predict long-term graft survival.
• There is a need for better endpoints to evaluate interventions targeting long-term outcomes.

Discussion:

• Candidate surrogate endpoints for long-term graft failure include estimated glomerular filtration rate, proteinuria, histological lesions, and donor-specific anti-human leukocyte antigen antibodies.
• Composite scoring systems may offer a more comprehensive approach to predicting long-term outcomes.
• The European Medicines Agency (EMA) has provided recommendations on the use of surrogate endpoints in kidney transplantation clinical studies.

Key Insights:

• Short-term efficacy endpoints do not reliably predict long-term graft survival in kidney transplant recipients.
• Validated models incorporating multiple factors are better suited to predict complex late graft failure.
• Clearer definition and validation of surrogate endpoints are essential for regulatory approval of long-term outcome therapies.

Outlook:

• Further research and consensus are needed to establish robust surrogate endpoints for kidney transplant clinical trials.
• The development of effective surrogate endpoints could facilitate conditional marketing authorization for novel therapies.
• Improved endpoints will enhance the evaluation of interventions aimed at improving the longevity of kidney allografts.